Tourmaline Bio (TRML) AI Stock Analysis

• Market Cap: $390.68M
• Dividend Yield: N/A
• Average Volume (3M): 317.49K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.39
• Revenue Growth: N/A
• EPS Growth: 74.59%
• Country: US
• Employees: 74
• Sector: Healthcare
• Sector Strength: 62
• Industry: Biotechnology
• EPS (TTM): -2.88
• Shares Outstanding: 25,685,429
• 10 Day Avg. Volume: 369,440
• 30 Day Avg. Volume: 317,494
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -5.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $54.14
• Price Target Upside: 280.20% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

Tourmaline Bio's score reflects the inherent challenges of its financial performance with no revenue and significant operational losses. While the company benefits from a strong cash position, the reliance on external financing and overbought technical indicators suggest caution. The lack of earnings and guidance further complicates valuation, resulting in a low overall score.

Positive Factors

Market Opportunity

Shares trading around $300M present a favorable risk/reward scenario with potential upside to the mid-$50s.

Product Profile

Pacibekitug targets IL-6 to reduce inflammation, addressing a largely unaddressed area in atherosclerotic cardiovascular disease.

Safety Profile

Pacibekitug trials showed no infection concerns, which strengthens its safety profile.

Strategic Development

Favorable Paci data can attract significant business development interest.

Negative Factors

Clinical Trials

Topline data from the Phase 2 TRANQUILITY trial of pacibekitug in atherosclerotic cardiovascular disease remain on track, representing an important catalyst for TRML shares.

Competition

There is a 30-50%+ downside on lack of differentiation from Zilti.

Tourmaline Bio Business Overview & Revenue Model

Company Description

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

How the Company Makes Money

Tourmaline Bio makes money primarily through the development and commercialization of its proprietary biologic therapies. The company generates revenue by licensing its technology and products to larger pharmaceutical firms, entering into strategic partnerships that provide upfront payments, milestone payments, and royalties on future sales. Additionally, Tourmaline Bio might receive funding from government grants and research collaborations that support its drug development efforts. As its pipeline matures, the company also aims to benefit from direct sales of its approved therapies.

Tourmaline Bio Financial Statement Overview

Summary

Tourmaline Bio's financials reflect a typical biotechnology company in its R&D stage, with no revenue and high operational losses. While the strong cash position provides a buffer, the reliance on external financing and lack of revenue generation remain key challenges. The firm must secure successful clinical developments or partnerships to transition towards revenue generation.

Income Statement

Tourmaline Bio has consistently reported zero revenue over the years, reflecting its early-stage development phase typical of biotechnology firms. The company has negative EBIT and net income, indicating ongoing operational losses without revenue streams. This is characteristic of firms in R&D phases but highlights a risk due to lack of revenue generation.

Balance Sheet

The company maintains a healthy cash position with cash and short-term investments of $258 million as of the most recent report. Despite having minimal debt, the equity ratio is high due to negative net income. This positions the firm with a relatively stable financial structure but also underscores reliance on equity financing and potential dilution risks.

Cash Flow

Tourmaline Bio's cash outflow from operations is significant, reflecting high R&D expenditures. The free cash flow is negative, indicating cash consumption without revenue support. However, substantial financing inflows suggest active capital raising to support operations, which is crucial for sustaining cash needs in the absence of revenue.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-33.00K	-6.00K	-623.00K	-447.00K
	EBIT
-89.73M	-45.41M	-19.70M	-904.00	-22.68M
	EBITDA
-89.73M	-45.38M	-19.70M	-46.88M	-22.24M
	Net Income Common Stockholders
-73.21M	-42.12M	-19.70M	-904.00	-22.71M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
258.30M	202.95M	8.26M	150.00K	149.49M
	Total Assets
309.00M	210.29M	9.10M	150.00K	152.78M
	Total Debt
244.00K	415.00K	504.00K	150.00K	0.00
	Net Debt
-30.26M	-140.31M	-7.75M	0.00	-17.59M
	Total Liabilities
8.95M	5.25M	28.83M	376.00K	4.77M
	Stockholders Equity
300.05M	205.04M	-19.73M	-226.00K	148.00M
Cash Flow		Free Cash Flow
-77.27M	-28.14M	-11.53M	-42.42M	-20.50M
	Operating Cash Flow
-77.26M	-28.08M	-6.46M	-39.99M	-19.21M
	Investing Cash Flow
-194.31M	3.84M	-5.07M	-96.39M	-133.30M
	Financing Cash Flow
161.35M	156.72M	19.85M	137.40M	131.12M

Tourmaline Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 14.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRML, the sentiment is Negative. The current price of 14.24 is below the 20-day moving average (MA) of 16.27, below the 50-day MA of 15.12, and below the 200-day MA of 19.08, indicating a bearish trend. The MACD of 0.23 indicates Positive momentum. The RSI at 39.36 is Neutral, neither overbought nor oversold. The STOCH value of 11.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRML.

Tourmaline Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TALK	59 Neutral	$431.20M	429.03	0.97%	―	25.02%	―
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
ZVRA	45 Neutral	$405.33M	―	-207.84%	―	-14.02%	-72.44%
KROS	43 Neutral	$413.33M	―	-41.46%	―	2250.99%	3.52%
ORIC	42 Neutral	$396.33M	―	-54.73%	―	―	7.15%
TRML	37 Underperform	$390.68M	―	-28.99%	―	―	74.59%
ERAS	32 Underperform	$388.07M	―	-43.68%	―	―	10.38%

Tourmaline Bio Corporate Events

Tourmaline Bio Updates on Clinical Progress and Outlook

Tourmaline Bio has released an updated corporate presentation detailing its progress and future plans, including significant clinical trial milestones for its lead product, pacibekitug. The company is well-financed, with cash expected to fund operations into 2027, positioning it to achieve key milestones that could enhance its market position and provide value to stakeholders.

Tourmaline Bio Unveils Clinical Progress and New Indication

Tourmaline Bio announced key updates at its Investor Day, highlighting progress in its clinical trials and strategic priorities. The company reported over-enrollment in its Phase 2 TRANQUILITY trial and introduced a new indication for pacibekitug, abdominal aortic aneurysm, while planning further developments contingent on trial outcomes, positioning itself for potential expansion in cardiovascular inflammation treatment.